Company / Return on Equity (ROE)
Bionano Genomics, Inc. Return on Equity (ROE) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-59.4%
FY2025
5-year range
-316.7% / -21.5%
FY2021-FY2025
Trend
+81.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Bionano Genomics, Inc. reports negative total equity of -59.4% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-59.4% in FY2025 with a 5-year CAGR of +57.8%.
Improved from -241.8% to -59.4% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -6.3pp
- 5-Year Change
- +57.8pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 81.2% year-over-year.
- Peak return on equity (roe) was recorded in FY2021.
- Lowest return on equity (roe) in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -8.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -59.4% | +81.2% |
| FY2024 | -316.7% | -31.0% |
| FY2023 | -241.8% | -354.7% |
| FY2022 | -53.2% | -147.4% |
| FY2021 | -21.5% | +81.7% |
| FY2020 | -117.2% | +85.8% |
| FY2019 | -825.2% | -352.3% |
| FY2018 | -182.5% | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 22, 2026